

# The Journal of Rheumatology

VOLUME 38: NO. 7

jrheum.org

JULY 2011

## Editorials

- All That Glitters Is Not Gold — Standardizing Diagnosis in Rheumatoid Arthritis Studies K.P. Liao, V. Bykerk ..... 1223  
Who's Holding up the Queue? Delay in Treatment of Rheumatoid Arthritis J.E. Homik ..... 1225  
Rehabilitation for Ankylosing Spondylitis in the Era of Biologics: Any Room Left for This Treatment? E. Lubrano, S. D'Angelo, A. Spadaro, C. Palazzi, I. Olivieri ..... 1228  
Should Clinicians Start Measuring Flow Mediated Dilation Response in Patients with Systemic Lupus Erythematosus? C.S. Lau ..... 1231

## Review

- Challenges in Diagnosing Latent TB Infection in Patients Treated with TNF Antagonists E.C. Keystone, K.A. Papp, W. Wobeser ..... 1234

## Articles

- Lymphotoxin- $\alpha$  252 A>G Polymorphism: A Link Between Disease Susceptibility and Dyslipidemia in RA? M.J. Santos, D. Fernandes, J. Caetano-Lopes, et al ..... 1244  
Diagnostic Accuracy of ACR/EULAR 2010 Criteria for RA in a 2-Year Cohort S. Varache, D. Corne, J. Morvan, et al ..... 1250  
Incidence and Risk Factors for Serious Infection in Patients with RA Treated with TNF Inhibitors: A Report from the Registry of Japanese RA Patients for Longterm Safety Y. Komano, M. Tanaka, T. Nanki, et al, for the REAL Study Group ..... 1258  
A Comparison Between IgG- and IgA-class Antibodies to CCP and to Modified Citrullinated Vimentin in Early RA and Very Early Arthritis A. Svärd, A. Kastbom, M.K. Söderlin, Å. Reckner-Olsson, T. Skogh ..... 1265  
Persistence with Anti-TNF Therapies in Patients with RA: Observations from the RADIUS Registry J.A. Markenson, A. Gibofsky, W.R. Palmer, et al ..... 1273  
Time to Treatment for New Patients with RA in a Major Metropolitan City S. Jamal, S.M.H. Alibhai, E.M. Badley, C. Bombardier ..... 1282  
Prognostic Indicators of Hospitalized Patients with SLE: A Large Retrospective Multicenter Study in China X. Feng, Y. Zou, W. Pan, et al ..... 1289

## Endothelium-dependent But Not Endothelium-independent Flow-mediated Dilatation Is Significantly Reduced in Patients with SLE without Vascular Events: A Metaanalysis and Metaregression

- A. Mak, Y. Liu, R.C-M Ho ..... 1296  
Longterm Followup After Tapering MMF During Maintenance Treatment for Proliferative Lupus Nephritis K. Laskari, A.G. Tzioufas, A. Antoniou, H.M. Moutsopoulos ..... 1304  
Quantitative Data for Care of Patients with SLE in Usual Clinical Settings: A Patient Multidimensional HAQ and Physician Estimate of Noninflammatory Symptoms A.D. Askanase, I. Castrejón, T. Pincus ..... 1309

## Late-age Onset SSc

- R.L. Manno, F.M. Wigley, A.C. Gelber, L.K. Hummers ..... 1317  
Expert Agreement on EULAR/EUSTAR Recommendations for the Management of SSc K.M. Walker, J. Pope, on behalf of the Scleroderma Clinical Trials Consortium and the Canadian Scleroderma Research Group ..... 1326

## Malignancies in Italian Patients with SSc Positive for Anti-RNA Polymerase III Antibodies P. Airo', A. Ceribelli, I. Cavazzana, M. Taraborelli, S. Zingarelli, F. Franceschini ..... 1329

- Rehabilitation Treatment in Patients with AS Stabilized with TNF Inhibitor Therapy. A Randomized Controlled Trial S. Masiero, L. Bonaldo, M. Pigatto, A. Lo Nigro, R. Ramonda, L. Punzi ..... 1335

## The SPARCC Registry for SpA

- D.D. Gladman, P. Rahman, R.J. Cook, et al ..... 1343

## Resolution of Inflammation Following Treatment of AS Is Associated with New Bone Formation S.J. Pedersen, P. Chiowchanwisawakit, R.G.W. Lambert, M. Østergaard, W.P. Maksymowych ..... 1349

- Effectiveness and Safety of Etanercept in Patients with PsA in a Canadian Clinical Practice Setting: The REPARe Trial D.D. Gladman, C. Bombardier, C. Thorne, et al ..... 1355

## High Prevalence of Subclinical Left Ventricular Dysfunction in Patients with PsA

- Q. Shang, L-S. Tam, G.W-K. Yip, et al ..... 1363

## Prevalence of Thyroid Autoimmunity in Patients with SpA

- R. Peluso, G.A. Lupoli, A. Del Puente, et al ..... 1371

## Candidate Genes in Patients with Autoinflammatory Syndrome Resembling TNF Receptor-associated Periodic Syndrome Without Mutations in the TNFRSF1A Gene

- S. Borghini, M. Fiore, M. Di Duca, et al ..... 1378

|                                                                                                                                                                                                                                                             |      |
|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------|
| <b>Febuxostat in Gout: Serum Urate Response in Uric Acid Overproducers and Underexcretors</b> <i>D.S. Goldfarb, P.A. MacDonald, B. Hunt, L. Gunawardhana</i> . . . . .                                                                                      | 1385 |
| <b>Consistency of Knee Pain and Risk of Knee Replacement: The Multicenter OA Study</b> <i>B.L. Wise, D.T. Felson, M. Clancy, et al.</i> . . . . .                                                                                                           | 1390 |
| <b>Bisphosphonate-associated Osteonecrosis of the Jaw in Ontario: A Survey of Oral and Maxillofacial Surgeons</b> <i>A.A. Khan, L.P. Rios, G.K.B. Sandor, et al</i> . . . . .                                                                               | 1396 |
| <b>Longterm Therapeutic Response to Milnacipran Treatment for FM. A European 1-Year Extension Study Following a 3-Month Study</b> <i>J.C. Branco, P. Cherin, A. Montagne, A. Bouroubi, on behalf of the Multinational Coordinator Study Group</i> . . . . . | 1403 |
| <b>Specialized Rheumatology Nurse Substitutes for Rheumatologists in the Diagnostic Process of FM: A Cost-Consequence Analysis and RCT</b> <i>M.E. Kroese, J.L. Severens, G.J. Schulpen, M.C. Bessems, F.J. Nijhuis, R.B. Landewé</i> . . . . .             | 1413 |

## Pediatric Rheumatology

|                                                                                                                                                                                                                                                          |      |
|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------|
| <b>Heterotopic Ossification of the TMJ in JIA</b> <i>S. Ringold, M. Thapa, E.A. Shaw, C.A. Wallace</i> . . . . .                                                                                                                                         | 1423 |
| <b>MBL Expression Genotype in Pediatric-onset SLE: Associations with Susceptibility to Renal Disease and Protection Against Infections</b> <i>Y-C. Tsai, K-W. Yeh, T-C. Yao, Y-L. Huang, M-L. Kuo, J-L. Huang</i> . . . . .                              | 1429 |
| <b>Safety and Efficacy of Rituximab in Severe Juvenile DM: Results from 9 Patients from the French Autoimmunity and Rituximab Registry</b> <i>B. Bader-Meunier, H. Decaluwe, C. Barnerias, et al, for the Club Rhumatismes et Inflammation</i> . . . . . | 1436 |
| <b>Development of IBD in Patients with JIA Treated with Etanercept</b> <i>T.D. van Dijken, S.J. Vastert, V.M. Gerloni, et al</i> . . . . .                                                                                                               | 1441 |

## Images in Rheumatology

|                                                                                                                 |      |
|-----------------------------------------------------------------------------------------------------------------|------|
| <b>Fluorescence Optical Imaging of Juvenile Arthritis</b> <i>S.G. Werner, H-E. Langer, G. Horneff</i> . . . . . | 1447 |
|-----------------------------------------------------------------------------------------------------------------|------|

## OMERACT 10

### 10th International Consensus Conference on Outcome Measures in Rheumatology Kota Kinabalu, Borneo - May 4-8, 2010

|                                                                                                                                                                                                                |      |
|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------|
| <b>Introduction</b> . . . . .                                                                                                                                                                                  | 1448 |
| <b>Disease-specific Outcomes</b>                                                                                                                                                                               |      |
| <b>Patient-reported Outcomes in Chronic Gout: A Report from OMERACT 10</b> <i>J.A. Singh, W.J. Taylor, L.S. Simon, et al</i> . . . . .                                                                         | 1452 |
| <b>Tophus Measurement as an Outcome Measure for Clinical Trials of Chronic Gout: Progress and Research Priorities</b> <i>N. Dalbeth, F.M. McQueen, J.A. Singh, et al</i> . . . . .                             | 1458 |
| <b>Serum Urate in Chronic Gout – Will It Be the First Validated Soluble Biomarker in Rheumatology?</b> <i>L.K. Stamp, P.P. Khanna, N. Dalbeth, et al</i> . . . . .                                             | 1462 |
| <b>Bringing It All Together: A Novel Approach to the Development of Response Criteria for Chronic Gout Clinical Trials</b> <i>W.J. Taylor, J.A. Singh, K.G. Saag, et al</i> . . . . .                          | 1467 |
| <b>Development of Outcome Measures for Large-vessel Vasculitis for Use in Clinical Trials: Opportunities, Challenges, and Research Agenda</b> <i>H. Direskeneli, S.Z. Aydin, T.A. Kermani, et al</i> . . . . . | 1471 |

|                                                                                                                                                                                                                                                            |      |
|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------|
| <b>The OMERACT Core Set of Outcome Measures for Use in Clinical Trials of ANCA-associated Vasculitis</b> <i>P.A. Merkel, S.Z. Aydin, M. Boers, et al</i> . . . . .                                                                                         | 1480 |
| <b>Toward Development of a FM Responder Index and Disease Activity Score: OMERACT Module Update</b> <i>P.J. Mease, D.J. Clauw, R. Christensen, et al, and the OMERACT Fibromyalgia Working Group</i> . . . . .                                             | 1487 |
| <b>Development of a Disease Severity and Responder Index for PsA — Report of the OMERACT 10 PsA SIG</b> <i>L.C. Coates, A. Mumtaz, P.S. Helliwell, et al</i> . . . . .                                                                                     | 1496 |
| <b>Endorsement of Definitions of Disease Activity States and Improvement Scores for the AS Disease Activity Score: Results from OMERACT 10</b> <i>P.M.M.C. Machado, R.B.M. Landewé, D.M. van der Heijde</i> . . . . .                                      | 1502 |
| <b>Early Postoperative Mortality Following Joint Arthroplasty: A Systematic Review</b> <i>J.A. Singh, J. Kundukulam, D.L. Riddle, V. Strand, P. Tugwell</i> . . . . .                                                                                      | 1507 |
| <b>Developing Disease Activity and Response Criteria in CTD-related ILD</b> <i>L.A. Saketkoo, E.L. Matteson, K.K. Brown, J.R. Seibold, V. Strand; for the Connective Tissue Disease-related Interstitial Lung Disease Special Interest Group</i> . . . . . | 1514 |

## Correspondence

|                                                                                                                        |      |
|------------------------------------------------------------------------------------------------------------------------|------|
| <b>Where in the World is Oral Triamcinolone?</b> <i>L. Roger</i> . . . . .                                             | 1519 |
| <b>Reply R. Alten</b> . . . . .                                                                                        | 1519 |
| <b>Lupus Related Longitudinal Myelitis</b> <i>D.M. Wingerchuk, B.G. Weinshenker</i> . . . . .                          | 1520 |
| <b>Reply P. Zotos</b> . . . . .                                                                                        | 1521 |
| <b>Coexistent WG and Goodpasture's Disease: What Is the Mechanism?</b> <i>J.I. Shin, S.J. Park, J.H. Kim</i> . . . . . | 1521 |
| <b>Who Discovered the ESR?</b> <i>A. Grzybowski, J.J. Sak</i> . . . . .                                                | 1521 |
| <b>Reply E.L. Matteson, C.S. Crowson</b> . . . . .                                                                     | 1523 |

## Letters

|                                                                                                                                                                                                                                                                      |      |
|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------|
| <b>Serum Levels of HMGB1 in Postmenopausal Patients with RA: Associations with Proinflammatory Cytokines, Acute-phase Reactants, and Clinical Disease Characteristics</b> <i>R. Pullerits, V. Urbanovicite, R.E. Voll, H. Forsblad-D'Elia, H. Carlsten</i> . . . . . | 1523 |
| <b>Acute Presentation of Tophaceous Myelopathy</b> <i>E. Levin, K. Hurth, R. Joshi, R. Brasington</i> . . . . .                                                                                                                                                      | 1525 |
| <b>AS Refractory to TNF Blockade Responds to Tocilizumab</b> <i>J-D. Cohen, R. Ferreira, C. Jorgensen</i> . . . . .                                                                                                                                                  | 1527 |
| <b>Positive C-ANCA with PR3 Specificity Glomerulonephritis in a Patient with Subacute Bacterial Endocarditis</b> <i>M. Uh, I.A. McCormick, J.T. Kelsall</i> . . . . .                                                                                                | 1528 |
| <b>Primary Aldosteronism Simulating Polymyositis</b> <i>Y-C. Tang, S-K. Wang, W-L. Yuan</i> . . . . .                                                                                                                                                                | 1529 |

## Corrections

|                                                                                                                                                                                                              |      |
|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------|
| <b>Intraarticular Botulinum Toxin A for Refractory Painful Total Knee Arthroplasty: A Randomized Controlled Trial</b> <i>J.A. Singh, M.L. Mahowald, S. Noorbaloochi</i> . . . . .                            | 1534 |
| <b>Anti-Fibrillarin Antibody in African American Patients with Systemic Sclerosis: Immunogenetics, Clinical Features, and Survival Analysis</b> <i>S. Sharif, M.J. Fritzler, M.D. Mayes, et al</i> . . . . . | 1534 |
| <b>Meetings in Rheumatology</b> . . . . .                                                                                                                                                                    | xi   |